GTCR’s $200M Pledge To Actient Could Go Higher
This article was originally published in The Pink Sheet Daily
Executive Summary
Sale of Ovation to Lundbeck makes funds available for even bigger specialty-pharma plays.
You may also be interested in...
Lundbeck Looks To Replace Lexapro Earnings Through Ovation Purchase
Acquisition will enhance Lundbeck’s CNS pipeline and add a needed U.S. specialty sales force.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.